0
0
Global demand for dependable antibiotic intermediate sourcing has intensified as pharmaceutical manufacturers face tightening regulatory scrutiny, raw material price volatility, and the recurring challenge of inconsistent batch quality that interrupts production schedules. For procurement and quality teams evaluating a certified pharmaceutical intermediate supplier for the antibiotic industry, the presence of formal quality system documentation and structured product development management is often the determining factor in supplier selection. Shandong Tianming Pharmaceutical Group, operating under the brand name Tianming Pharmaceutical, illustrates how an integrated R&D-production enterprise organizes its anti-infective intermediate supply chain around ISO9001 compliance and an IPD (Integrated Product Development) management system.
Why Certification Matters for Antibiotic Intermediate Sourcing
Quality certification is not a formality in antibiotic intermediate manufacturing; it is the documentation trail that downstream API and formulation customers rely on for their own regulatory filings. Within the Tianming Pharmaceutical Group structure, Shandong Sihuan Pharmaceutical Co., Ltd. holds ISO9001 Quality Management System Certification (2025), and Guangxi Tianming Pharmaceutical Co., Ltd. holds its own ISO9001 certification (2024). These certifications sit alongside a GMP-compliant quality assurance system that governs raw material receipt, in-process control, and finished product release across the group's production bases. The company has also been recognized as a National High-Tech Enterprise at multiple subsidiary levels — Shandong Sihuan Pharmaceutical Co., Ltd. (2024), Shandong Tianming Pharmaceutical Technology Co., Ltd. (2025), and Guangxi Tianming Pharmaceutical Co., Ltd. (2023) — a designation that reflects sustained R&D investment and technical capability rather than a one-time audit.
Tianming Pharmaceutical's Anti-Infective Product Portfolio
Tianming Pharmaceutical's anti-infective product line is positioned specifically around intermediates and API building blocks for antibacterial and antiviral drugs, including beta-lactamase inhibitors, cephalosporin intermediates, and antiviral agents, with target customers spanning API manufacturers and CDMO institutions serving anti-infective drug markets.
Beta-Lactamase Inhibitor Chain
At the center of this portfolio is Avibactam Sodium (CAS 1192491-61-4), supported by a sequence of upstream intermediates that trace the full synthesis pathway: O-Benzylhydroxylamine Hydrochloride (CAS 2687436), (2S,5R)-Phenoxyamide piperidine-2-carboxylic acid ethyl ester oxalate (CAS 1416134-48-9), (2S,5R)-5-[(Benzyloxy)amino]piperidine-2-carboxamide dihydrochloride (CAS 1416134-49-0), (2S,5R)-6-Benzyloxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (CAS 1192651492), and the Avibactam Core Nucleus (CAS 1416134-53-6). Supplying this full chain from a single source removes the coordination burden of sourcing each intermediate from a different vendor — a pain point the company identifies directly as fragmented sourcing across multiple suppliers raising procurement costs.
Cephalosporin Core Nucleus Intermediates
The cephalosporin segment includes 4-Methylquinazoline-5-carboxaldehyde (CAS 82294700), 3,5-Dichloro-4-pyridone-1-acetic acid, known as DCPA (CAS 56187372), Cefmenoxime Core Nucleus Hydrochloride, also referred to as 7-ATCA HCl (CAS 68350027), and (6R,7R)-7-Amino-3-[(5-methyltetrazol-2-yl)thio]methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, known as 7-MTCA (CAS 82549517), together with Benzathine Cefapirin (CAS 97468376). The anti-infective category further extends into antiviral chemistry with Tenofovir Alafenamide Fumarate (CAS 1392275567), its precursor [[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethyl]methyl]phosphonic acid monophenyl ester (CAS 379270356), and Tenofovir Alafenamide (CAS 379270378), as well as Baricitinib (CAS 1187594097), Moxifloxacin (CAS 249243295), and Baloxavir Marboxil (CAS 1985606141).
The IPD Management System Behind Consistent Quality
Behind this product range sits an IPD integrated product development management system that governs how each intermediate moves from laboratory small-scale synthesis through process pilot to industrial scale-up. This framework is supported by two R&D centers — in Jinan and Nanjing — with over 6,000 square meters of combined laboratory space and more than RMB 40 million invested in professional R&D and testing equipment, including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments. Quality traceability is maintained through full batch records covering raw material receipt, reaction parameters, purification processes, and testing data, with every record archived for complete chain-of-custody traceability. A CRM, ERP, and BPM digital management system layer coordinates order management, inventory, production scheduling, and customer service, which the company states supports rapid domestic order confirmation and full international logistics chain services.
Manufacturing Scale and Delivery Reliability
Production is distributed across three coordinated bases: Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Shandong; Jining Tianming Pharmaceutical Co., Ltd. in Jining, Shandong; and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi, Guangxi. Together these sites operate more than 160 reactor vessels and maintain annual production capacity in the hundreds of tons. For antibiotic intermediate customers, this translates into gram-level to ton-level supply options spanning laboratory R&D quantities through commercial-scale orders. In-stock orders are delivered within 7 to 15 working days, covering order confirmation, quality review, packaging, and shipping, while made-to-order lead times depend on synthesis complexity, workshop scheduling, and raw material availability. Expedited production scheduling is available for urgent projects.
Service Model Supporting Global Anti-Infective Supply Chains
Tianming Pharmaceutical's service structure pairs each account with a 1-on-1 account manager and a technical engineer. Routine technical questions receive reference solutions within 2 hours, and more complex technical issues are documented in a written report within 24 hours. The company reports 2,000+ cooperative customers across domestic pharmaceutical industry clusters in East China, North China, and South China, plus international markets across more than 30 countries and regions in South Asia, Southeast Asia, the Middle East, Central and South America, and Africa. For cross-border orders, the service scope includes logistics coordination, customs clearance, and trade insurance support, alongside complete technical documentation — COA, MOA methodology, impurity profile studies, and stability data — intended to support customer DMF and CEP global regulatory filings.
Honors and Qualifications Underpinning Trust
Beyond ISO9001 and National High-Tech Enterprise status, subsidiaries within the group hold additional provincial recognitions, including Shandong Province Gazelle Enterprise and Guangxi Gazelle Enterprise designations, Shandong Province Specialized and Innovative SME and Guangxi Specialized and Innovative Enterprise status, and Shandong Province and Guangxi Innovative SME recognitions. The group's R&D output has also been acknowledged through the Dezhou Science and Technology Progress Second Prize for an anti-tumor drug preparation method (2022) and the Dezhou Science and Technology Progress Third Prize for a DPP-4 inhibitor class diabetes drug preparation method (2020), reflecting a broader pattern of applied process chemistry capability that extends across the company's full intermediate portfolio, including its anti-infective product lines.
A Structured Choice for Anti-Infective Procurement Teams
For pharmaceutical and CDMO organizations evaluating suppliers of antibiotic-related intermediates — whether beta-lactamase inhibitor precursors, cephalosporin core nuclei, or antiviral building blocks — the combination of ISO9001-certified quality systems, an IPD-managed development process, GMP-compliant production across three bases, and full-documentation support for regulatory filings gives Tianming Pharmaceutical Group a structured basis for supply chain qualification. The company's own stated positioning as an R&D-driven pharmaceutical raw material and intermediate enterprise operating an integrated R&D-production model, offering API, intermediates, and CMO/CDMO custom development and production solutions, reflects this certification-and-process-driven approach to serving the global anti-infective drug market.
Tianming Pharmaceutical Group
